BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Alcobra Ltd. (“Alcobra” or the “Company”) (NASDAQ: ADHD) concerning the Company and its officers’ potential violation of federal securities laws.
Alcobra is a biopharmaceutical company that focuses on the development and commercialization of oral drug candidates.
On January 17, 2017, Alcobra disclosed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, did not satisfy its primary endpoint in a Phase 3 trial.
On this news, Alcobra stock fell over 50%, to close at just $0.94 per share on January 17, 2017.
If you purchased Alcobra securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.